Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Imatinib
Gleevec and Taxotere · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Gleevec and Taxotere |
| Name | Type | Description |
|---|---|---|
| Gleevec and Taxotere | DRUG | Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15 |
Inclusion Criteria: * One prior chemotherapy treatment: use of single chemotherapy or a regimen containing more than one drug. Regimen must have a platinum agent (cisplatin or carboplatin). Prior biological treatment won't be counted as chemotherapy treatment. Chemoradiation or prior induction or a...
Top 20 of 76 competitors
Gleevec is being studied for use in prostate cancer and lung cancer. It is an investigational small molecule oncology drug being evaluated in Phase 2 clinical trials for these indications. Gleevec is also known as imatinib.
Gleevec is a kinase inhibitor, belonging to the -tinib class of drugs. It works by targeting kinases, which are enzymes involved in cell signaling and growth. This mechanism is relevant to its evaluation in cancer treatment.
Gleevec is developed by Novartis AG, a company traded on the stock exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate Gleevec for prostate cancer and lung cancer.
Gleevec is in Phase 2 clinical development for prostate cancer and lung cancer. It is an investigational drug, meaning it has not been approved by regulatory authorities for these uses and is still undergoing clinical evaluation.
Gleevec has been studied in two completed Phase 2 trials. NCT00222144 evaluated Gleevec with Taxotere in recurrent non-small cell lung cancer with 23 participants. NCT00251225 studied imatinib with docetaxel in prostate cancer with 49 male participants. Both trials were conducted in the United States.
Yes, Gleevec is the same as imatinib. Imatinib is the generic name for the drug, while Gleevec is a brand name. Clinical trials may refer to the drug by either name, such as in NCT00251225 which uses imatinib in its title.